USA-based BioCryst Pharmaceuticals (Nasdaq: BCRX) has licensed Rapivab (peramivir injection) for the treatment of influenza to Australia’s CSL Limited (ASX: CSL).
Rapivab is an intravenous treatment indicated in the USA for acute uncomplicated influenza in adults 18 years and older. It is also currently licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world, according to BioCryst.
Rapivab will be commercialized by CSL's subsidiary bioCSL, which specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze